Results from 111 patients with HER2 IHC 3 + across 20 cancer types in DESTINY-PanTumor02 demonstrated an ORR of 51.4% (95% CI: 41.7–61.0) and mDOR of 19.4 months (range: 1.3–27.9 +). This evidence concerns the gene ERBB2 and cancer.